The modern primary care clinic is a crowded, complicated place. A patient might come in for a diabetes check, leave with a referral for a sleep study, and be told to schedule a separate appointment for weight management. It's a system of referrals and waiting lists, one that often leaves chronic conditions like hypertension or low testosterone in a holding pattern. DirectCare AI, a South Florida startup founded in 2025, is betting it can close those gaps with a single, AI-supported platform. It offers direct-to-consumer virtual clinics for buzzy, high-demand treatments like GLP-1 weight loss and testosterone replacement therapy (TRT), while also selling its remote patient monitoring software to traditional clinics trying to manage those same patients [DirectCare AI, Unknown].
The Dual-Pronged Wedge
DirectCare AI's strategy operates on two fronts, a dual approach that speaks to the fragmentation of the current market. For patients, it functions as a virtual specialty clinic, offering online consultations with US-licensed physicians for GLP-1 medications, hormone replacement, hair loss, and sexual health. The company handles remote prescription and medication delivery, promising a concierge-like experience for conditions that often require navigating multiple specialists [DirectCare AI, Unknown]. For healthcare institutions, it sells an AI-enabled platform for Remote Patient Monitoring (RPM) and Chronic Care Management (CCM). This software aims to help overburdened primary care practices track patient vitals from home, flagging potential issues for earlier intervention [DirectCare AI, Unknown]. The bet is that the same underlying technology can serve both a direct consumer brand and a B2B software layer, with the chronic care data from one side potentially informing the personalized protocols of the other.
| Segment | Offering | Key Differentiator |
|---|---|---|
| Direct-to-Consumer | Virtual clinics for GLP-1, TRT, HRT, hair loss, sexual health | Physician-supervised plans, AI personalization, medication delivery [Newswire, March 2025] |
| Healthcare Institutions (B2B) | AI-powered Remote Patient Monitoring (RPM) & Chronic Care Management (CCM) platforms | Helps clinics modernize care, close infrastructure gaps, and track chronic conditions [DirectCare AI, Unknown] |
The Founder's Council Seat
The company is led by solo founder Scott Hozebin, who serves as its CEO. His public profile is anchored by a seat on the Forbes Technology Council, a curated community for senior tech executives [Forbes Councils, 2024]. This affiliation provides a degree of external validation for his leadership, though the company's early-stage nature means there is no public track record of prior healthtech exits or scaled operational experience. Hozebin is also listed as a managing director at MetaEquity Partners and has held advisory roles, including at digital health company Better Health [Forbes Business Development Council, 2025]. This suggests a background blending growth advisory and healthcare, a relevant mix for a company navigating both patient acquisition and clinical workflows. The team structure beyond the CEO is not detailed in public materials, and the company has posted listings for marketing and data analyst interns, indicating a lean, foundational build-out [LinkedIn, Unknown].
The Unanswered Questions of Scale
The ambition is clear, but the path to scaling a capital-intensive, compliance-heavy telehealth operation is lined with open questions. The most immediate is funding. DirectCare AI has not disclosed any institutional investment rounds, which could mean it is bootstrapped, funded quietly by angels, or still seeking its first major check. In a sector where customer acquisition costs for direct-to-consumer telehealth can be steep and regulatory compliance requires significant legal and clinical oversight, undisclosed funding raises questions about runway and scaling capacity.
- Regulatory navigation. While the company states it uses US-licensed physicians, the telehealth landscape for prescribing controlled substances like testosterone and certain weight-loss medications is a patchwork of state laws. Sustained growth requires meticulous, state-by-state compliance that has tripped up larger players.
- Clinical depth vs. convenience. The model prioritizes access and convenience. The risk is being perceived as a transactional medication provider rather than a comprehensive care partner, especially without the deep integration into a patient's full medical history that a traditional health system might offer.
- The institutional sale. Selling RPM software to clinics is a different motion than selling TRT to consumers. It requires longer sales cycles, integration with electronic health records, and proving return on investment in a crowded market with established players.
The company's rebuttal, implied in its materials, is that its AI layer is the differentiator. It's not just a telehealth front-end; it's the intelligence that manages titration, monitors side effects from connected devices, and helps clinicians prioritize outreach. That claim, however, awaits the peer-reviewed validation that Pulse Raman's beat demands.
For patients seeking treatment for conditions like obesity or hypogonadism, the standard of care today is often a frustrating maze. It involves a primary care referral to an endocrinologist or a specialty clinic, long wait times for appointments, and complex insurance prior authorizations for expensive medications. Out-of-pocket cash-pay clinics have filled the gap, but with varying degrees of medical oversight. DirectCare AI is aiming for that precise patient population: adults navigating chronic metabolic and hormonal conditions who are willing to pay for a streamlined, technology-enabled path to treatment. Its success hinges on proving that its model is not just convenient, but clinically sound and sustainable beyond the initial prescription.
Sources
- [DirectCare AI, Unknown] DirectCare AI | AI-Powered Health Guidance & Remote Monitoring | https://www.directcare.ai/
- [Newswire, March 2025] DirectCare AI Review: Best Remote TRT Service in 2025 | https://www.newswire.com/news/directcare-ai-review-best-remote-trt-service-in-2025-22617005
- [Forbes Councils, 2024] Scott Hozebin | Chief Executive Officer (CEO) - DirectCare AI | https://councils.forbes.com/profile/Scott-Hozebin-Chief-Executive-Officer-CEO-DirectCare-AI/02c9c5d0-a6ea-4d62-b6a2-a2723e9d1148
- [Forbes Business Development Council, 2025] Scott Hozebin - Forbes Business Development Council | https://www.forbes.com/councils/forbesbusinessdevelopmentcouncil/people/scotthozebin/
- [LinkedIn, Unknown] Scott Hozebin M.B.A - DirectCare AI | LinkedIn | https://www.linkedin.com/in/scotthozebin/